Nikko Asset Management Americas Inc. 13D/13G Filings for CRISPR Therapeutics AG (CRSP)

Nikko Asset Management Americas Inc. 13D and 13G filings for CRISPR Therapeutics AG:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-02-12
6:22 pm
Sale
2023-12-3113GCRISPR Therapeutics AG
CRSP
Nikko Asset Management Americas Inc.3,369,762
4.240%
-636,714decrease
(-15.89%)
Filing
2023-02-10
10:30 am
Sale
2022-12-3113GCRISPR Therapeutics AG
CRSP
Nikko Asset Management Americas Inc.4,006,476
5.110%
-312,995decrease
(-7.25%)
Filing
2022-02-14
06:05 am
Purchase
2021-12-3113GCRISPR Therapeutics AG
CRSP
Nikko Asset Management Americas Inc.4,319,471
5.640%
482,648increase
(+12.58%)
Filing
2021-02-11
5:14 pm
Purchase
2020-12-3113GCRISPR Therapeutics AG
CRSP
Nikko Asset Management Americas Inc.3,836,823
5.390%
787,270increase
(+25.82%)
Filing
2020-02-12
3:19 pm
Purchase
2019-12-3113GCRISPR Therapeutics AG
CRSP
Nikko Asset Management Americas Inc.3,049,553
5.080%
3,049,553increase
(New Position)
Filing